Skip to main content
. Author manuscript; available in PMC: 2011 Apr 28.
Published in final edited form as: N Engl J Med. 2010 Oct 28;363(18):1693–1703. doi: 10.1056/NEJMoa1006448

Figure 3. Best Response to Crizotinib in 31 Patients with ALK-Positive Tumors, as Correlated with Clinicopathological Characteristics.

Figure 3

Percent tumor response, treatment duration, smoking history, and selected tumor characteristics are listed in the table below the graph, with each table entry corresponding to a patient in the graph above. Patients are listed in order of increasing percentage response to crizotinib, with listed patient numbers corresponding to those in Figure 2A. Smoking history is reported in pack-years. The EML4-ALK genotype is reported as the EML4 exon that is fused to ALK, as assayed by nucleotide sequencing of RT-PCR products. U denotes undetermined for patients for whom RT-PCR assays using primers to ALK exon 20 along with EML4 exons 6, 13, and 18 produced no product. Blank fields indicate that adequate tumor samples were not available for analysis. ALK expression is reported as 0, 1+, 2+, or 3+, per convention for immunohistochemical analysis.